It was found to promote KRASG12D-induced lung cancer through phosphorylation of FADD at Ser194 [80]; CK1α inhibition prevented acquired drug resistance to erlotinib in epidermal growth factor receptor-mutant NSCLC [179]. Here, CSNK1A1 is linked to lung cancer.